Backed by Indian biosim giant Biocon, bispecifics player Bicara debuts with $40M and solid tumors on the radar

Kyle Blankenship

Best known stateside for its biosimilars pact with Mylan, Indian generics player Biocon has long run a much smaller R&D unit for in-house oncology drugs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Backed by Indian biosim giant Biocon, bispecifics player Bicara debuts with $40M and solid tumors on the radar

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: Bucking gene-editing downturn, Tune raises $175M to bring epigenetic editing to clinic

Biogen offers to buy out struggling neuro partner Sage Therapeutics

Chasing the next wave of obesity drugs, Metsera files for an IPO

Four biotechs emerge with $800M and in-licensed assets on Friday

Exclusive: Moderna's former top scientist has a new startup using AI to improve mRNA therapies

Updated: CDER Director Patrizia Cavazzoni to step down ahead of Trump presidency

Backed by In­di­an biosim gi­ant Bio­con, bis­pecifics play­er Bicara de­buts with $40M and sol­id tu­mors on the radar

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Backed by Indian biosim giant Biocon, bispecifics player Bicara debuts with $40M and solid tumors on the radar